Crizanlizumab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jun 10, 2021 → Jun 10, 2031
NCT ID
NCT04657822About Crizanlizumab
Crizanlizumab is a approved stage product being developed by Novartis for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04657822. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03720626 | Pre-clinical | Active |
| NCT05469828 | Phase 1/2 | Recruiting |
| NCT04662931 | Approved | Completed |
| NCT04657822 | Approved | Recruiting |
| NCT04435184 | Phase 2 | Completed |
| NCT03938454 | Phase 2 | Completed |
| NCT03474965 | Phase 2 | Completed |
| NCT03264989 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Disease